Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Priority Review Vouchers For Pediatric Rare Disease: Will Popularity Force A Quick Halt?

Related Content

FDA Accelerated Approval For Rare Diseases Again Under Congressional Pressure

Jul 30 2013

For Sale: Knight Therapeutics Seeks Buyers For Impavido Priority Review Voucher

Mar 20 2014

BioMarin Tests FDASIA’s Pediatric Voucher Waters With <em>Vimizim</em> Approval

Feb 24 2014

FDASIA Study Mandates Focus On Performance, But Could Slow Reviews

Aug 20 2012

Pediatric Study Planning With FDA, EMA To Be More Closely Aligned

Dec 10 2012

Priority Review Voucher Value Still Confounds, But Remains An Incentive For Sponsors

Sep 21 2011

Targeted Therapies On FDA’s Orphan Designation Radar

Apr 29 2013

Related Companies

BioMarin Pharmaceutical Inc.

Knight Therapeutics, Inc.

Additional Topics

United States Drug Approval Standards BioPharmaceutical

More from United States

More from North America

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window